ADAP Adaptimmune Therapeutics PLC

By Michael Dabaie

Adaptimmune Therapeutics plc said results are positive from its updated clinical and translational data from the pivotal trial of afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

The company said it will present the data at the Connective Tissue Oncology Society annual meeting.

The cancer-focused cell therapy company said efficacy data validate the meaningful clinical benefit of afami-cel, the company said. Based on the reported overall response rate, the trial will meet its primary endpoint in the final analysis planned later this year, Adaptimmune said.

As of Sept. 1, overall response rate was 34% with a disease control rate of 85% per Independent Review in 47 heavily pre-treated patients. Durability of responses is encouraging, and the median duration of response hasn't been reached, the company said.

"The positive results presented at CTOS further validate the potential of this therapy to address a great unmet medical need for patients with synovial sarcoma and MRCLS," said Elliot Norry, Adaptimmune's chief medical officer. "We are confident that these data will support our BLA filing for afami-cel next year."

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

November 11, 2021 09:45 ET (14:45 GMT)

Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024

Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024